G. Haerter, B. Manfras, Markus Mueller
Apr 9, 2004
Citations
1
Influential Citations
38
Citations
Quality indicators
Journal
AIDS
Abstract
Antiretroviral therapy against HIV has resulted in various metabolic alterations and body fat redistributions. The lipodystrophy syndrome is most often seen in HIV-infected patients treated with protease inhibitors (PI). Atazanavir is a novel and potent PI without relevant lipid elevations. Here, we report on three patients with rapid regression of dorsocervical and abdominal fat accumulations, respectively, after switching antiretroviral therapy from established PI to atazanavir.